No Data
No Data
Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Market Cap Surged CN¥2.3b Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded
Asymchem Inaugurates Its First European Small Molecule Development and API Pilot Plant Manufacturing Site at Discovery Park in Sandwich, Kent, UK
Asymchem Laboratories (002821.SZ): Cumulative expenditure of 999.6 million yuan to repurchase 12,300,700 shares.
Asymchem Laboratories (002821.SZ) announced that as of July 31, 2024, the company accumulated 12.3007 million shares of the company's A shares through the repurchase of special securities accounts under the centralized bidding method, accounting for 3.5976% of the company's total A shares. The highest fill price was 102.00 yuan/share, the lowest fill price was 71.65 yuan/share, and the total amount paid was 0.9996 billion yuan (excluding transaction costs).
China International Capital Corporation: Peptide production ushers in the opportunities of the times with the rapid expansion of GLP-1.
In terms of the global pattern, Swiss companies are leading in peptide production, while China is the main supplier of GLP-1 active pharmaceutical ingredients.
Changes in the CRO concept stocks rose in the morning, with Wuxi Apptec's quarterly net income increasing compared to the previous quarter, and Pharmaron achieving a double-digit growth in newly signed order amounts.
On July 31st, CRO concept stocks rose in early trading. As of press time, Wuxi Bio (02269.HK) rose 8.19% to HK$11.36; Wuxi AppTec (02359.HK) rose 8.04% to HK$32.25; Tigermed (03347.HK) rose 7.59% to HK$29.75; Asymchem Laboratories (06821.HK) rose 5.98% to HK$47; Pharmaron (03759.HK) rose 5.97% to HK$9.59. Market information source: Futubull. On the news front, the evening of July 29th.
Shanghai supports the use of AI technology in drug research and development, and continues to increase its support for the development of innovative drugs.
On July 30, the Shanghai Municipal People's Government Office issued several opinions on supporting the innovative development of the entire biomedical industry chain.
No Data